BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form
NeXstar Pharmaceuticals, Inc. One focus of the new company will
be the liposomal delivery of oligonucleotides. The company's initial
product, AmBisome, is a liposomal formulation of amphotericin
B, which has been approved for marketing in 16 countries for the
treatment of life-threatening systemic fungal infections that
fail to respond to conventional amphotericin B therapy.
A phase III trial of the product in conjunction with the National
Cancer Institute has recently been announced.